Antipeptic Ulcer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Antipeptic Ulcer Drugs Market is segmented By Product (Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs), By Application (Duodenal Ulcers, Gastritis, Gastric Ulcers, Gastroesophageal Reflux Disease (GERD)), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)– Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Antipeptic Ulcer Drugs Market is estimated to reach at a CAGR of 4% during the forecast period (2024-2031).

Antiulcer agents and medications for acid peptic disease are commonly used drugs that rarely cause liver injury. Both classes of antiulcer medications block the pathways of acid production or secretion, decreasing gastric acidity, improving symptoms and aiding in healing of acid-peptic diseases.

Antipeptic Ulcer Drugs Market Scope

For More Insights Request Free Sample

Antipeptic Ulcer Drugs Market Dynamics

The anti-peptic ulcer drug market growth is driven by the rising prevalence of peptic ulcers, growing R&D activities due to government support and policies and increasing adoption of triple therapy. Moreover, the rising preference of patients to consume drugs instead of surgical procedures is driving the market growth in the forecast period.

Rising prevalence of peptic ulcer, is expected to drive the growth in the forecast period

A peptic ulcer is one of the serious medical problems. According to Harvard Health Publishing, every year, peptic ulcers affect more than 4 million people in the U.S. Additionally, it occurs irrespective of the age bracket, and it is estimated that 1 in 10 individuals are likely to develop this disease at some point in their life. The increasing prevalence of peptic ulcer disease drives the demand for effective anti-peptic ulcer drugs across the globe.

Growing R&D activities and strong pipeline of new drugs, is expected to drive the growth in the forecast period

The rising prevalence of peptic ulcer disease globally propels the key industry players to invest in R&D activities. This results in the new drug launches for the treatment of peptic ulcer disease, which has a positive impact on market growth. For instance, in November 2019, RedHill Biopharma Ltd. received USFDA approval for RHB-105 (Talicia) to treat Helicobacter pylori in adults.

The conduction of clinical trials for new drugs to overcome the complications related to the currently available drugs is another factor likely to fuel the market growth during the forecast period. For instance, according to clinicaltrials.gov, Takeda Pharmaceuticals has a drug Vonoprazan fumarate in Phase 3 trials, the drug of category potassium-competitive acid blockers (P-CABs) for peptic ulcer disease treatment.

Side effects associated with peptic ulcer drugs is likely to hamper the market growth

Side effects associated with proton pump inhibitors like nutritional deficiency (magnesium, Vit B12), increased risk of gastroenteritis, bowel upset, diarrhea, gastric ulcers and duodenal ulcers, and side-effects associated with anticholinergic drugs include urine retention, dry mouth, and constipation may restrict the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has led to the halt of several industrial processes causing unprecedented economic loss. However, pharmaceutical companies are thriving in these difficult times owing to the increasing demand for medication drugs across the globe. Likewise, the demand for these ulcer drugs is experiencing considerable growth as major pharmaceutical companies focus on R&D activities to develop new drugs and cater to the demand for OTC drugs across several stores. The market is, therefore, expected to showcase positive growth during the forecast period.

Antipeptic Ulcer Drugs Market Segment Analysis

The proton-pump inhibitor segment is expected to hold largest share in this market segment

Treatment of peptic ulcers in Helicobacter pylori-positive patients should include antimicrobial therapy to eradicate the infection; based on considerations of primary antimicrobial resistance and safety, one recommended regimen is the combination of a proton-pump inhibitor. They do so by irreversibly inhibiting the stomach's H⁺/K⁺ ATPase proton pump. They also have true efficacy and cost-effectiveness in preventing NSAID-associated ulcer complications, such as bleeding and perforation.

The duodenal ulcers segment is expected to hold largest share in this market segment

The growing prevalence of duodenal ulcers and the rising awareness about therapeutic launches for its treatment are some of the factors attributable to its dominance during the forecast period. For instance, in July 2019, ANI Pharmaceuticals, in partnership with Appco Pharma, announced the launch of generic ranitidine capsules to treat duodenal ulcers.

The retail pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Peptic ulcer medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost antipeptic ulcer drugs market growth.

Antipeptic Ulcer Drugs Market Geographical Share

North America region holds the largest market share of global antipeptic ulcer drugs market

North America region is expected to hold a dominant position in the global anti-peptic ulcer drugs market over the forecast period, owing to increasing research and development activities, increasing incidence of peptic ulcers in the U.S. that drives the demand for peptic ulcer drugs in the region. For instance, according to Harvard Health Publishing, peptic ulcers affect more than 4 million people in the U.S every year. For instance, in May 2020, researchers from the Michael E. De-Bakey veterans’ affairs medical center received FDA approval for the three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule RHB-105, which effectively eradicates helicobacter pylori infection in adults.

Antipeptic Ulcer Drugs Market Companies and Competitive Landscape:

The global antipeptic ulcer drugs market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include Eisai Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., HeliCure AB, AstraZeneca PLC, Ore Pharmaceuticals, Inc, Zydus Cadila, Abbott Laboratories, Pfizer, GlaxoSmithKline, Sihuan Pharmaceutical, Huadong Medicine, Xian Janssen pharmaceutical, Yangtze River pharmaceutical, Changzhou siyao pharmaceuticals. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in July 2019, Zydus Cadila received USFDA approval for Misoprostol tablets for stomach ulcers.

Antipeptic Ulcer Drugs Market Key Companies to Watch

AstraZeneca PLC

Overview: AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine.

Product Portfolio: The Company’s portfolio comprised of oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Key Developments: In April 2018, AstraZeneca in partnership with Daiichi Sankyo launched Nexium 10mg and 20mg granules for suspension, a proton pump inhibitor for the peptic ulcer treatment.